Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 31
6.
J Ayub Med Coll Abbottabad ; 35(4): 675-679, 2023.
Article En | MEDLINE | ID: mdl-38406959

Takotsubo syndrome (TTS), Takotsubo cardiomyopathy, or stress-induced cardiomyopathy are interchangeable terms characterized by transient left ventricular systolic dysfunction, electrocardiographic changes, and cardiac biomarker elevation similar to acute coronary syndrome (ACS), without the presence of obstructive epicardial coronary artery disease. It predominantly affects postmenopausal females and manifests in the presence of stressful triggers such as severe physical or emotional stress, natural disasters, unexpected death of relatives, acute medical illnesses, etc. TTS was initially considered to be a benign condition however recent studies have shown that it may be associated with complications and mortality similar to ACS. Rare reports of TTS triggered by diabetic ketoacidosis (DKA) have been published. Herein we describe a case of an elderly female with a history of type II diabetes mellitus (DM) who was admitted with DKA and subsequently developed TTS that resolved after treatment of DKA and implementation of heart failure therapies.


Acute Coronary Syndrome , Coronary Artery Disease , Diabetes Mellitus, Type 2 , Diabetic Ketoacidosis , Takotsubo Cardiomyopathy , Humans , Female , Aged , Takotsubo Cardiomyopathy/etiology , Takotsubo Cardiomyopathy/complications , Diabetic Ketoacidosis/complications , Diabetes Mellitus, Type 2/complications , Coronary Artery Disease/complications
7.
J Ayub Med Coll Abbottabad ; 34(Suppl 1)(3): S723-S724, 2022.
Article En | MEDLINE | ID: mdl-36414601

ST-segment elevation myocardial infarction (STEMI) is a rare presentation in patients with anomalous coronary arteries. Among these patients, identification of the culprit lesion remains challenging. Furthermore, the default transradial approach advocated by the guidelines and professional societies, especially for acute coronary syndromes may pose technical challenges for the interventionalists.


Acute Coronary Syndrome , Myocardial Infarction , Percutaneous Coronary Intervention , ST Elevation Myocardial Infarction , Humans , ST Elevation Myocardial Infarction/diagnosis , ST Elevation Myocardial Infarction/surgery
11.
Am J Cardiol ; 154: 29-32, 2021 09 01.
Article En | MEDLINE | ID: mdl-34272042

Hemodynamic support is widely utilized for unprotected left main (ULM) percutaneous coronary interventions (PCI) despite lack of evidence from randomized studies and the risk of device-related complications. We aimed to compare ULMPCI with and without intra-aortic balloon pump (IABP) support. A single-center, retrospective analysis was performed for patients undergoing ULMPCI with and without IABP support. Clinical, procedural, in-hospital, and 30-day cardiovascular outcomes were compared. From 2003 through 2018, 217 patients underwent non-emergent ULMPCI, 55 with elective IABP support (IABP group), and 162 without support (No-IABP group). The study population comprised 56.4% men and 74.5% Caucasians in the IABP group and 53.7% men and 62.3% Caucasians in the No-IABP group. The mean age for IABP and No-IABP group patients was 75.75 ± 12.34 years and 73.47 ± 15.19 years, respectively (p = 0.315). Procedural success was achieved in 99% of IABP and 95.3% of No-IABP patients (p = 0.089). In-hospital and 30-day mortality was 5.5% for the IABP group and 5.6% for the No-IABP group (p = 0.977). Rates of major complications were statistically similar between the groups. Bailout IABP was required in 10% of No-IABP patients. Hospital and intensive care unit length of stay was statistically longer in the IABP group. In conclusion, ULMPCI without IABP support was not associated with increased mortality and major cardiovascular outcomes compared with supported patients and was associated with shorter hospital and intensive care unit stay. A randomized trial comparing unsupported versus supported ULMPCI is warranted to identify patients who would benefit from hemodynamic support.


Coronary Artery Disease/surgery , Hospital Mortality , Intra-Aortic Balloon Pumping/methods , Length of Stay/statistics & numerical data , Percutaneous Coronary Intervention/methods , Postoperative Complications/epidemiology , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Intensive Care Units , Male , Middle Aged , Mortality , Retrospective Studies , Treatment Outcome
13.
J Electrocardiol ; 65: 28-33, 2021.
Article En | MEDLINE | ID: mdl-33482618

Takotsubo Cardiomyopathy (TC) is a syndrome characterized by reversible left ventricular dysfunction in the presence of possible emotional or physical triggers but without evidence of obstructive coronary artery disease. It has become increasingly reported worldwide and is associated with significant morbidity and mortality. TC may present with an array of electrocardiographic (ECG) findings. These ECG findings, if accurately interpreted, can play an important role in the diagnosis and risk stratification of this syndrome. In the last three decades since the disease was first described, multiple diagnostic criteria have been established. The key diagnostic tools for TC include clinical symptomatology, cardiac biomarkers, non-invasive cardiac imaging, and coronary angiography. The ECG findings in TC can be variable, however, some ECG scores have been proposed in association with TC with reasonably good diagnostic sensitivity and specificity. This article aims to provide a succinct review of important electrocardiographic findings associated with TC and its impact on clinical outcomes.


Coronary Artery Disease , Takotsubo Cardiomyopathy , Coronary Angiography , Diagnosis, Differential , Electrocardiography , Humans , Takotsubo Cardiomyopathy/diagnosis
17.
Cardiovasc Revasc Med ; 21(2): 230-234, 2020 02.
Article En | MEDLINE | ID: mdl-31767523

BACKGROUND/PURPOSE: We assessed commonly reported patient- and circuit-related adverse events involving extracorporeal membrane oxygenation (ECMO) devices by analyzing post-marketing surveillance data from the Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database. ECMO is a rescue therapy for critically ill patients requiring oxygenation and cardiopulmonary support. Key configurations include veno-venous (VV) ECMO for respiratory support and veno-arterial (VA) ECMO for cardio-respiratory support. Robust data on the most commonly reported complications associated with ECMO therapy are limited. METHODS/MATERIALS: The MAUDE database was queried from January 1, 2009, through March 31, 2019, yielding 93 reports. After excluding duplicate reports, 82 reports were included in the final analysis. RESULTS: Percentages represent the proportion of total submitted MAUDE reports on ECMO. Of the reported cases, 24 were VV-ECMO, 8 were VA-ECMO, and the remainder were unspecified. The most commonly reported patient-related adverse events included hemodynamic decompensation of patients (12.2%), death (12.2%), atrial perforation (7.3%), and bleeding (7.3%). The most commonly reported failure modes were in the following circuit components: mechanical pump (19.5%, mostly due to technical failure or clots), membrane oxygenator (19.5%, mostly due to tear in the membrane or temperature probe), and access cannulae (18.3%, mostly due to structural damage). CONCLUSIONS: Analysis of the MAUDE database demonstrates that in real-world practice, ECMO devices are associated with important complications. With broadened global utilization of ECMO devices, standard complication and failure reporting policies may improve patient selection, operator proficiency, and existing device technology. SUMMARY: An analysis of the Food and Drug Administration's Manufacturer and User Facility Device Experience database demonstrates that in real-world practice, extracorporeal membrane oxygenation devices are associated with serious complications. The most commonly reported patient-related adverse events were hemodynamic decompensation of patients and death, and the most commonly reported failure modes were in the device's mechanical pump and membrane oxygenator.


Device Approval , Extracorporeal Membrane Oxygenation/adverse effects , Extracorporeal Membrane Oxygenation/instrumentation , Heart Diseases/therapy , Oxygenators, Membrane/adverse effects , Product Surveillance, Postmarketing , Respiratory Insufficiency/therapy , United States Food and Drug Administration , Databases, Factual , Equipment Failure , Extracorporeal Membrane Oxygenation/mortality , Heart Diseases/diagnosis , Heart Diseases/mortality , Heart Diseases/physiopathology , Hemodynamics , Humans , Patient Safety , Respiratory Insufficiency/diagnosis , Respiratory Insufficiency/mortality , Respiratory Insufficiency/physiopathology , Risk Assessment , Risk Factors , Treatment Failure , United States
18.
World J Cardiol ; 11(9): 213-216, 2019 Sep 26.
Article En | MEDLINE | ID: mdl-31572564

Takotsubo syndrome is a wide spectrum disease with a dramatic clinical presentation mimicking acute coronary syndrome albeit without obstructive coronary disease and typically manifests in the backdrop of intense emotional or physical trigger. Pathophysiology is incompletely understood with multifactorial mechanistic pathways circling around a heart-brain-endocrine axis. Several anatomic and phenotypic variants exist with varied clinical manifestations. The aftermath of Takotsubo syndrome is not always benign and both short- and long-term complications can occur which may impact its prognosis. Several gaps in knowledge exist providing an impetus for tremendous future research opportunities.

...